Louis E. Schroder

614 total citations
16 papers, 457 citations indexed

About

Louis E. Schroder is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Louis E. Schroder has authored 16 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Louis E. Schroder's work include Radiopharmaceutical Chemistry and Applications (5 papers), Medical Imaging and Pathology Studies (5 papers) and Bone health and treatments (4 papers). Louis E. Schroder is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (5 papers), Medical Imaging and Pathology Studies (5 papers) and Bone health and treatments (4 papers). Louis E. Schroder collaborates with scholars based in United States and Germany. Louis E. Schroder's co-authors include Harry R. Maxon, Jonathan S. Moulton, Craig C. Williams, Vicki Hertzberg, R. C. Samaratunga, Gary J. Ehrhardt, Stephen Thomas, Emanuela Englaro, Howard I. Scher and Herbert J. Smith and has published in prestigious journals such as Journal of the American College of Cardiology, Radiology and Urology.

In The Last Decade

Louis E. Schroder

16 papers receiving 438 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Louis E. Schroder United States 8 326 245 209 141 30 16 457
Paul Macleod United Kingdom 6 241 0.7× 224 0.9× 254 1.2× 170 1.2× 21 0.7× 8 461
Rosella Pasqualoni Italy 11 257 0.8× 214 0.9× 132 0.6× 112 0.8× 24 0.8× 13 368
S. Vasanthan United Kingdom 7 162 0.5× 151 0.6× 183 0.9× 77 0.5× 20 0.7× 11 318
Nicole Barthélémy Belgium 9 257 0.8× 131 0.5× 399 1.9× 110 0.8× 18 0.6× 17 503
Serenella Bergomi Italy 7 219 0.7× 162 0.7× 114 0.5× 101 0.7× 11 0.4× 11 308
Guido Ventroni Italy 11 235 0.7× 59 0.2× 144 0.7× 152 1.1× 18 0.6× 19 472
S. Houston United Kingdom 5 456 1.4× 285 1.2× 296 1.4× 135 1.0× 10 0.3× 8 609
Anna Vaughn United States 6 253 0.8× 91 0.4× 449 2.1× 197 1.4× 32 1.1× 7 552
N. Coliarakis Greece 5 172 0.5× 270 1.1× 427 2.0× 73 0.5× 36 1.2× 8 549
Marc Van den Eynde Belgium 6 153 0.5× 188 0.8× 159 0.8× 101 0.7× 15 0.5× 11 424

Countries citing papers authored by Louis E. Schroder

Since Specialization
Citations

This map shows the geographic impact of Louis E. Schroder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louis E. Schroder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louis E. Schroder more than expected).

Fields of papers citing papers by Louis E. Schroder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louis E. Schroder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louis E. Schroder. The network helps show where Louis E. Schroder may publish in the future.

Co-authorship network of co-authors of Louis E. Schroder

This figure shows the co-authorship network connecting the top 25 collaborators of Louis E. Schroder. A scholar is included among the top collaborators of Louis E. Schroder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louis E. Schroder. Louis E. Schroder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Kurz, Thomas, Reinhard Vonthein, Louis E. Schroder, et al.. (2024). Effect of Valve Type and Anesthesia Strategy for TAVR. Journal of the American College of Cardiology. 85(1). 74–82. 2 indexed citations
2.
Schroder, Louis E., Danika L. Lew, Robert C. Flanigan, et al.. (2001). Phase II evaluation of suramin in advanced renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 6(4). 145–148. 2 indexed citations
3.
Cualing, Hernani, et al.. (2001). Allergic Granulomatosis Secondary to a Limited Form of Churg-Strauss Syndrome. Archives of Pathology & Laboratory Medicine. 125(7). 954–957. 7 indexed citations
4.
Macdonald, John S., Joth Jacobson, Manuel Modiano, et al.. (2000). A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: a Southwest Oncology Group Study (SWOG 9413). Investigational New Drugs. 18(3). 269–273. 15 indexed citations
5.
Grunberg, Steven M., John Crowley, Kenneth R. Hande, et al.. (1999). Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemotherapy and Pharmacology. 44(6). 461–468. 15 indexed citations
6.
Maxon, Harry R., Louis E. Schroder, Lee C. Washburn, et al.. (1998). Rhenium-188(Sn)HEDP for treatment of osseous metastases.. PubMed. 39(4). 659–63. 71 indexed citations
7.
Schroder, Louis E., et al.. (1997). Phase II evaluation of doxorubicin/vinblastine combined with inhibitors trifluoperazine/verapamil of P-glycoprotein in patients with advanced renal carcinoma. Urologic Oncology Seminars and Original Investigations. 3(3). 94–98. 1 indexed citations
8.
Maxon, Harry R., Stephen R. Thomas, Vicki Hertzberg, et al.. (1992). Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Seminars in Nuclear Medicine. 22(1). 33–40. 62 indexed citations
9.
Englaro, Emanuela, Louis E. Schroder, Stephen Thomas, Craig C. Williams, & Harry R. Maxon. (1992). Safety and Efficacy of Repeated Sequential Administrations of Re-186(Sn)HEDP as Palliative Therapy for Painful Skeletal Metastases. Clinical Nuclear Medicine. 17(1). 41–44. 19 indexed citations
10.
Maxon, Harry R., Louis E. Schroder, Vicki Hertzberg, et al.. (1991). Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.. PubMed. 32(10). 1877–81. 128 indexed citations
11.
Breneman, John C., Sandra E. Mitchell, Douglas K. Hawley, Bernard S. Aron, & Louis E. Schroder. (1991). Concurrent Radiotherapy and Chemotherapy for Locally Advanced Non-Small-Cell Cancer of the Lung Report of a Clinical Trial and Review of the Literature. American Journal of Clinical Oncology. 14(1). 9–15. 7 indexed citations
12.
Silberstein, Edward B. & Louis E. Schroder. (1990). Minimal Bone Scan Findings in the Presence of Wide-Spread Osteobiastic Disease on Skeletal Radiography. Clinical Nuclear Medicine. 15(11). 816–817. 2 indexed citations
13.
Maxon, Harry R., Louis E. Schroder, Stephen R. Thomas, et al.. (1990). Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.. Radiology. 176(1). 155–159. 113 indexed citations
14.
Schroder, Louis E., Mark A. Weiss, & Chris Hughes. (1986). Squamous cell carcinoma of bladder: An increased incidence in blacks. Urology. 28(4). 288–291. 8 indexed citations
15.
Schroder, Louis E.. (1983). Bilateral Ureteral Obstruction due to Uric Acid Stones in Association With Immune Hemolytic Anemia. Archives of Internal Medicine. 143(5). 1020–1020. 3 indexed citations
16.
Schroder, Louis E., et al.. (1979). [Clinical classification of the severity of lung injuries (author's transl)].. PubMed. 33 Suppl 1. 436–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Macleod Breakdown of academic impact, for papers by Rosella Pasqualoni Breakdown of academic impact, for papers by S. Vasanthan Breakdown of academic impact, for papers by Nicole Barthélémy Breakdown of academic impact, for papers by Serenella Bergomi Breakdown of academic impact, for papers by Guido Ventroni Breakdown of academic impact, for papers by S. Houston Breakdown of academic impact, for papers by Anna Vaughn Breakdown of academic impact, for papers by N. Coliarakis Breakdown of academic impact, for papers by Marc Van den Eynde
Rankless by CCL
2026